392 related articles for article (PubMed ID: 34490745)
1. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
Lee KJ; Moon JS; Kim NY; Ko JS
Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
4. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
[TBL] [Abstract][Full Text] [Related]
5. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
[TBL] [Abstract][Full Text] [Related]
6. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan.
Kitamoto T; Kitamoto A; Yoneda M; Hyogo H; Ochi H; Nakamura T; Teranishi H; Mizusawa S; Ueno T; Chayama K; Nakajima A; Nakao K; Sekine A; Hotta K
Hum Genet; 2013 Jul; 132(7):783-92. PubMed ID: 23535911
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
9. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
Lin YC; Chang PF; Chang MH; Ni YH
Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
[TBL] [Abstract][Full Text] [Related]
10. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
Cavalcante LN; Porto J; Mazo D; Longatto-Filho A; Stefano JT; Lyra AC; Carrilho FJ; Reis RM; Alves VAF; Sanyal AJ; Oliveira CP
Ann Hepatol; 2022; 27(6):100728. PubMed ID: 35710086
[TBL] [Abstract][Full Text] [Related]
11. Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population.
Chung GE; Lee Y; Yim JY; Choe EK; Kwak MS; Yang JI; Park B; Lee JE; Kim JA; Kim JS
Gut Liver; 2018 May; 12(3):316-323. PubMed ID: 29271184
[TBL] [Abstract][Full Text] [Related]
12. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
13. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.
Larrieta-Carrasco E; Flores YN; Macías-Kauffer LR; Ramírez-Palacios P; Quiterio M; Ramírez-Salazar EG; León-Mimila P; Rivera-Paredez B; Cabrera-Álvarez G; Canizales-Quinteros S; Zhang ZF; López-Pérez TV; Salmerón J; Velázquez-Cruz R
Exp Mol Pathol; 2018 Feb; 104(1):50-58. PubMed ID: 29307798
[TBL] [Abstract][Full Text] [Related]
15. Association of rs738409 Polymorphism in Adiponutrin Gene with Liver Steatosis and Atherosclerosis Risk Factors in Greek Children and Adolescents.
Stasinou E; Emmanouilidou-Fotoulaki E; Kavga M; Sotiriadou F; Lambropoulos AF; Fotoulaki M; Papadopoulou-Legbelou K
Nutrients; 2022 Aug; 14(17):. PubMed ID: 36079710
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
[TBL] [Abstract][Full Text] [Related]
18. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Lin YC; Chang PF; Chang MH; Ni YH
Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
[TBL] [Abstract][Full Text] [Related]
19. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
[TBL] [Abstract][Full Text] [Related]
20. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
